Developer docs
API playgroundTry for free, no card

Search company profiles

Teoxane Laboratories Geneva

Full company profile

uuid000aa5q

Namestring
Teoxane Laboratories Geneva
Legal namestring
TEOXANE SA
Websiteurl
teoxane.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Teoxane Laboratories Geneva (TEOXANE SA) is a Swiss medical aesthetics company founded in 2003 by Valérie Taupin in Geneva, specializing in the design, manufacture, and global commercialization of hyaluronic acid (HA)-based dermal fillers and dermocosmetics. The company operates through two principal product lines — the TEOSYAL PureSense range (with lidocaine for patient comfort, spanning indications from skin rehydration to volume restoration) and the TEOSYAL RHA (Resilient Hyaluronic Acid) collection, which is engineered to adapt to dynamic facial movement. Dermal fillers are regulated as Class III medical devices and complemented by a dermocosmetics range that includes the RHA Deep Repair Balm and the integrated R-Energy skin quality system.

The company's underlying technology centers on its proprietary RHA formulation and rheology work, supported by peer-reviewed clinical evidence and a dedicated R&D function in Geneva. Beyond injectables, Teoxane has developed proprietary injection protocols — notably the ATP framework and the MLT 3.1 (MultiLayering Technique) — which are taught through the Teoxane Global Academy. The product portfolio is sold under a hybrid go-to-market model: a B2B enterprise channel targeting licensed healthcare professionals (dermatologists, plastic surgeons, aesthetic physicians) via 10 wholly-owned subsidiaries and a network of international distributors, supplemented by a direct-to-consumer e-commerce channel for dermocosmetics. Revance Therapeutics holds exclusive US distribution rights for the RHA product line, and Teoxane secures FDA approvals as a core regulatory pillar of US market access.

Teoxane serves healthcare professionals in over 90 countries, with a workforce of 251–500 employees drawn from 30 nationalities and a subsidiary footprint spanning France, Italy, Germany, the UK, Spain, Poland, Switzerland, Singapore, Australia, the United States, and Dubai (META). Revenue is generated through one-time product sales of injectable medical devices and consumer skincare, with pricing quote-based and negotiated through subsidiary sales teams and distribution partners rather than publicly listed. The company remains privately held, founder-led, and independent of external private equity or venture capital, with no public listing disclosed in source materials.

Short descriptiontext

Teoxane Laboratories Geneva is a Swiss medical aesthetics company founded in 2003 that designs, manufactures, and globally commercializes hyaluronic acid dermal fillers (TEOSYAL, RHA) and dermocosmetics, selling primarily to licensed healthcare professionals across 90+ countries via subsidiaries and distribution partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersGeneva, Switzerland
HQ citystring
Geneva
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
dermal fillers, hyaluronic acid injectables, aesthetic medicine devices, dermocosmetics skincare, medical aesthetics manufacturing
Industry2 codes
PRIMARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare
SECONDARYCRABAAAB
Treatment Skincare (Serums, Actives, Acne & Anti-aging)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Soap, Cleaning Compound, and Toilet Preparation Manufacturing3256
SIC code2 codes
  • Perfumes, Cosmetics & Other Toilet Preparations2844
  • Surgical & Medical Instruments & Apparatus3841
Product category
Medical Aesthetics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Dermal Filler Product Sales
TypeOne Time License
Description

Sale of HA-based dermal filler products to healthcare professionals and clinics. Products are sold as medical devices requiring professional administration.

2Dermocosmetics Sales
TypeOne Time License
Description

Sale of dermocosmetics (skincare) products directly to consumers through e-commerce and to healthcare professionals for patient recommendations.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1TEOSYAL
Description

Brand name for Teoxane's range of hyaluronic acid dermal fillers, including PureSense and RHA product lines.

teoxane.com
+3 more records
Core offering1 text field

Teoxane designs, manufactures, and globally distributes a complete range of hyaluronic acid (HA) dermal fillers under the TEOSYAL PureSense and TEOSYAL RHA product lines, sold as Class III medical devices exclusively to licensed healthcare professionals for facial rejuvenation, wrinkle correction, and volume restoration. The portfolio is complemented by a dermocosmetics skincare range (including RHA Deep Repair Balm and the R-Energy skin quality system) sold both to professionals for patient recommendations and directly to end consumers via the company's e-commerce platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Products approved and commercialized in 90+ countries worldwide
Product overview1 text field

Teoxane Laboratories Geneva offers a comprehensive portfolio of hyaluronic acid-based aesthetic solutions, consisting of two main dermal filler lines (TEOSYAL PureSense and TEOSYAL RHA) and dermocosmetics. The TEOSYAL PureSense line includes Redensity 1 (skin booster), Redensity 2 (under-eye treatment), Global Action, Deep Lines, Kiss (lip filler), Ultra Deep, and Ultimate - all containing 0.3% lidocaine for patient comfort. The TEOSYAL RHA (Resilient Hyaluronic Acid) line comprises RHA 1, RHA 2, RHA 3, RHA 4, RHA Kiss, and RHA Kiss VolumeLIDO, designed to adapt to facial movements for natural-looking results. The portfolio is complemented by dermocosmetics including RHA Deep Repair Balm and the R-Energy skin quality system that combines injectables with topical skincare. The company also developed proprietary injection techniques including the ATP (Assessment & Anatomy, Techniques, Products) approach and MLT (MultiLayering Technique) 3.1.

Product and service15 records
1TEOSYAL PureSense Redensity 1
CategoryDermal Filler
Description

Hyaluronic acid skin booster (15 mg/mL) with 0.3% lidocaine for skin rehydration, wrinkle improvement, and correction of skin ageing signs on the face, crow's feet, neck, and neckline. For use by licensed healthcare professionals.

2TEOSYAL PureSense Redensity 2
CategoryDermal Filler
Description

Hyaluronic acid filler with lidocaine for correction of fine lines and wrinkles and treatment of under-eye circles including the tear trough area. Expected lifetime of at least 12 months. For use by licensed healthcare professionals.

3TEOSYAL PureSense Global Action
CategoryDermal Filler
Description

Dermal filler with lidocaine for correction of moderate wrinkles and cutaneous depressions. Creates volume that corrects wrinkles and enhances contour. Expected lifetime of 12 to 18 months. For use by licensed healthcare professionals.

4TEOSYAL PureSense Deep Lines
CategoryDermal Filler
Description

Dermal filler with lidocaine for correction of deep wrinkles and cutaneous depressions. Expected lifetime of 12 to 18 months. For use by licensed healthcare professionals.

5TEOSYAL PureSense Kiss
CategoryDermal Filler
Description

Lip filler with 0.3% lidocaine for restoration of lip volume and correction of cutaneous depressions around the mouth. Expected lifetime of 12 to 18 months. For use by licensed healthcare professionals.

6TEOSYAL PureSense Ultra Deep
CategoryDermal Filler
Description

High-concentration hyaluronic acid filler (25 mg/mL) with lidocaine for facial contour remodelling, volume restoration and augmentation, and correction of deep wrinkles and folds in thick skin areas. Expected lifetime of 15 to 18 months. For use by licensed healthcare professionals.

7TEOSYAL PureSense Ultimate
CategoryDermal Filler
Description

Dermal filler with lidocaine for creation of volume that corrects cutaneous depressions or facial contours. Expected lifetime of 12 to 18 months. For use by licensed healthcare professionals.

8TEOSYAL RHA 1
CategoryDermal Filler
Description

Resilient hyaluronic acid filler for correction of fine lines including perioral rhytids, upper lip border, and philtrum. Expected lifetime of at least 12 months. For use by licensed healthcare professionals.

9TEOSYAL RHA 2
CategoryDermal Filler
Description

Resilient hyaluronic acid filler (23 mg/mL HA) with 0.3% lidocaine for filling linear facial wrinkles and skin creases such as mild to moderate nasolabial folds. Designed to adapt to facial dynamics. Expected lifetime of 12 to 18 months. For use by licensed healthcare professionals.

10TEOSYAL RHA 3
CategoryDermal Filler
Description

Resilient hyaluronic acid filler for filling deep facial wrinkles such as moderate to severe nasolabial folds, and FDA-authorized for lip augmentation. Designed to adapt to facial movements. Expected lifetime of 12 to 18 months. For use by licensed healthcare professionals.

11TEOSYAL RHA 4
CategoryDermal Filler
Description

Resilient hyaluronic acid filler for filling deep wrinkles and folds in thick skin areas such as moderate to severe nasolabial folds and cheek augmentation. FDA-approved with Mepivacaine for midface augmentation. Expected lifetime of 15 to 18 months. For use by licensed healthcare professionals.

12TEOSYAL RHA Kiss VolumeLIDO
CategoryDermal Filler
Description

Lip filler with lidocaine in the RHA collection for correction of moderate to severe dynamic facial wrinkles and folds, lip augmentation, and lip fullness. Expected lifetime of 12 months. For use by licensed healthcare professionals.

13TEOSYAL RHA Dynamic Volume
CategoryDermal Filler
Description

New generation resilient hyaluronic acid filler for cheek augmentation and correction of age-related midface contour deficiencies in adults aged 22 years or older. Uses unique rheology to adapt to facial movements, providing natural-looking results lasting up to one year. For use by licensed healthcare professionals.

14R-Energy Skin Quality System
CategorySkin Quality System
Description

Comprehensive skin quality approach combining skin boosters (Redensity 1, RHA 1) with advanced dermocosmetics to restore hydration, luminosity, and long-term skin vitality. Works to hydrate, improve elasticity, refine texture, and strengthen skin resilience.

15RHA Deep Repair Balm
CategoryDermocosmetic
Description

Post-procedure repair cream for skin recovery following aesthetic treatments. Part of the dermocosmetics product range, sold directly to consumers via the company e-commerce platform and through healthcare professionals for patient recommendations.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Revance Therapeutics
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Galderma is the global leader in dermatology aesthetics and the maker of Restylane, the largest HA dermal filler franchise directly competing with Teoxane's TEOSYAL RHA line. Both companies target the same HCP channel (dermatologists, plastic surgeons, aesthetic physicians) with comparable injectable HA products.

TypeDirect peer
Description

Prollenium manufactures the Revanesse line of HA dermal fillers, directly competing with Teoxane's RHA products in the global aesthetics market with similar technology positioning and HCP go-to-market.

3Evolus
TypeRegional player
Description

Evolus is a US-focused aesthetics company marketing Jeuveau (neuromodulator) and expanding into adjacent categories, competing with Teoxane indirectly for the same HCP aesthetic customer base in North America.

TypeDirect peer
Description

Merz Aesthetics markets Belotero Balance (HA filler) and Radiesse (calcium hydroxylapatite), competing directly with Teoxane's RHA and PureSense lines in the medical aesthetics channel. Both are privately-positioned mid-size aesthetics specialists with global distribution.

TypeEmerging player
Description

Hugel is a Korean aesthetics and botulinum toxin manufacturer that has expanded into HA dermal fillers, competing with Teoxane in the global market with cost-competitive offerings and growing regulatory approvals.

TypeDirect peer
Description

Sinclair Pharma (acquired by Huadong Medicine) markets HA dermal fillers (MaiLi) and complementary aesthetics products, making it a direct competitor to Teoxane in the premium HA filler category globally.

7LG Chem (Yvoire)
TypeEmerging player
Description

LG Chem's life sciences division markets Yvoire, a HA dermal filler line, competing with Teoxane in Asian and select global markets as part of a broader conglomerate-backed aesthetics push.

8Revance Therapeutics
TypeDirect peer
Description

Revance is Teoxane's exclusive US distribution partner for the RHA collection and also markets its own DAXI neuromodulator, making it both a channel partner and a competitor in the US medical aesthetics market serving the same HCPs.

TypeBroad incumbent
Description

AbbVie's Allergan Aesthetics division markets the Juvéderm collection (including Voluma XC, Teoxane's direct benchmark in the RHA Dynamic Volume Phase III trial). Both compete in facial rejuvenation HA fillers sold through HCPs globally.

TypeDirect peer
Description

Croma-Pharma is an Austrian family-owned manufacturer of HA-based dermal fillers and skincare, closely comparable to Teoxane as a European mid-size aesthetics specialist with similar product positioning and private ownership structure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries11 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Teoxane Laboratories Geneva

Medical Aestheticsteoxane.com

Teoxane Laboratories Geneva is a Swiss medical aesthetics company founded in 2003 that designs, manufactures, and globally commercializes hyaluronic acid dermal fillers (TEOSYAL, RHA) and dermocosmetics, selling primarily to licensed healthcare professionals across 90+ countries via subsidiaries and distribution partners.

What Teoxane Laboratories Geneva does

Teoxane Laboratories Geneva (TEOXANE SA) is a Swiss medical aesthetics company founded in 2003 by Valérie Taupin in Geneva, specializing in the design, manufacture, and global commercialization of hyaluronic acid (HA)-based dermal fillers and dermocosmetics. The company operates through two principal product lines — the TEOSYAL PureSense range (with lidocaine for patient comfort, spanning indications from skin rehydration to volume restoration) and the TEOSYAL RHA (Resilient Hyaluronic Acid) collection, which is engineered to adapt to dynamic facial movement. Dermal fillers are regulated as Class III medical devices and complemented by a dermocosmetics range that includes the RHA Deep Repair Balm and the integrated R-Energy skin quality system.

The company's underlying technology centers on its proprietary RHA formulation and rheology work, supported by peer-reviewed clinical evidence and a dedicated R&D function in Geneva. Beyond injectables, Teoxane has developed proprietary injection protocols — notably the ATP framework and the MLT 3.1 (MultiLayering Technique) — which are taught through the Teoxane Global Academy. The product portfolio is sold under a hybrid go-to-market model: a B2B enterprise channel targeting licensed healthcare professionals (dermatologists, plastic surgeons, aesthetic physicians) via 10 wholly-owned subsidiaries and a network of international distributors, supplemented by a direct-to-consumer e-commerce channel for dermocosmetics. Revance Therapeutics holds exclusive US distribution rights for the RHA product line, and Teoxane secures FDA approvals as a core regulatory pillar of US market access.

Teoxane serves healthcare professionals in over 90 countries, with a workforce of 251–500 employees drawn from 30 nationalities and a subsidiary footprint spanning France, Italy, Germany, the UK, Spain, Poland, Switzerland, Singapore, Australia, the United States, and Dubai (META). Revenue is generated through one-time product sales of injectable medical devices and consumer skincare, with pricing quote-based and negotiated through subsidiary sales teams and distribution partners rather than publicly listed. The company remains privately held, founder-led, and independent of external private equity or venture capital, with no public listing disclosed in source materials.

Teoxane Laboratories Geneva firmographics

Firmographics
Name
Teoxane Laboratories Geneva
Legal name
TEOXANE SA
Website
https://teoxane.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Teoxane Laboratories Geneva is a Swiss medical aesthetics company founded in 2003 that designs, manufactures, and globally commercializes hyaluronic acid dermal fillers (TEOSYAL, RHA) and dermocosmetics, selling primarily to licensed healthcare professionals across 90+ countries via subsidiaries and distribution partners.
Ownership category
akta.pro rank

Teoxane Laboratories Geneva industry classification

Industry
Product category
Medical Aesthetics
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Soap, Cleaning Compound, and Toilet Preparation Manufacturing (3256)
SIC
Perfumes, Cosmetics & Other Toilet Preparations (2844), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYCRABAAAF
Dermocosmetics & Medical-Grade Skincare
SECONDARYCRABAAAB
Treatment Skincare (Serums, Actives, Acne & Anti-aging)

Keywords

  • Dermal fillers
  • Hyaluronic acid injectables
  • Aesthetic medicine devices
  • Dermocosmetics skincare
  • Medical aesthetics manufacturing

Where Teoxane Laboratories Geneva is headquartered

Location

Headquarters

HQ city
Geneva
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Teoxane Laboratories Geneva business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Dermal Filler Product Sales: Sale of HA-based dermal filler products to healthcare professionals and clinics. Products are sold as medical devices requiring professional administration.
  2. Dermocosmetics Sales: Sale of dermocosmetics (skincare) products directly to consumers through e-commerce and to healthcare professionals for patient recommendations.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Teoxane Laboratories Geneva product offering

Product offering

Core offering

Teoxane designs, manufactures, and globally distributes a complete range of hyaluronic acid (HA) dermal fillers under the TEOSYAL PureSense and TEOSYAL RHA product lines, sold as Class III medical devices exclusively to licensed healthcare professionals for facial rejuvenation, wrinkle correction, and volume restoration. The portfolio is complemented by a dermocosmetics skincare range (including RHA Deep Repair Balm and the R-Energy skin quality system) sold both to professionals for patient recommendations and directly to end consumers via the company's e-commerce platform.

Product overview

Teoxane Laboratories Geneva offers a comprehensive portfolio of hyaluronic acid-based aesthetic solutions, consisting of two main dermal filler lines (TEOSYAL PureSense and TEOSYAL RHA) and dermocosmetics. The TEOSYAL PureSense line includes Redensity 1 (skin booster), Redensity 2 (under-eye treatment), Global Action, Deep Lines, Kiss (lip filler), Ultra Deep, and Ultimate - all containing 0.3% lidocaine for patient comfort. The TEOSYAL RHA (Resilient Hyaluronic Acid) line comprises RHA 1, RHA 2, RHA 3, RHA 4, RHA Kiss, and RHA Kiss VolumeLIDO, designed to adapt to facial movements for natural-looking results. The portfolio is complemented by dermocosmetics including RHA Deep Repair Balm and the R-Energy skin quality system that combines injectables with topical skincare. The company also developed proprietary injection techniques including the ATP (Assessment & Anatomy, Techniques, Products) approach and MLT (MultiLayering Technique) 3.1.

Differentiator

Problem solved

Functional benefit

Brands

  • TEOSYAL: Brand name for Teoxane's range of hyaluronic acid dermal fillers, including PureSense and RHA product lines.
  • RHA (Resilient Hyaluronic Acid)
  • TEOSYAL PureSense
  • Teoxane Global Academy

Products and services

  • TEOSYAL PureSense Redensity 1 Hyaluronic acid skin booster (15 mg/mL) with 0.3% lidocaine for skin rehydration, wrinkle improvement, and correction of skin ageing signs on the face, crow's feet, neck, and neckline. For use by licensed healthcare professionals.
  • TEOSYAL PureSense Redensity 2 Hyaluronic acid filler with lidocaine for correction of fine lines and wrinkles and treatment of under-eye circles including the tear trough area. Expected lifetime of at least 12 months. For use by licensed healthcare professionals.
  • TEOSYAL PureSense Global Action Dermal filler with lidocaine for correction of moderate wrinkles and cutaneous depressions. Creates volume that corrects wrinkles and enhances contour. Expected lifetime of 12 to 18 months. For use by licensed healthcare professionals.
  • TEOSYAL PureSense Deep Lines Dermal filler with lidocaine for correction of deep wrinkles and cutaneous depressions. Expected lifetime of 12 to 18 months. For use by licensed healthcare professionals.
  • TEOSYAL PureSense Kiss Lip filler with 0.3% lidocaine for restoration of lip volume and correction of cutaneous depressions around the mouth. Expected lifetime of 12 to 18 months. For use by licensed healthcare professionals.
  • TEOSYAL PureSense Ultra Deep High-concentration hyaluronic acid filler (25 mg/mL) with lidocaine for facial contour remodelling, volume restoration and augmentation, and correction of deep wrinkles and folds in thick skin areas. Expected lifetime of 15 to 18 months. For use by licensed healthcare professionals.
  • TEOSYAL PureSense Ultimate Dermal filler with lidocaine for creation of volume that corrects cutaneous depressions or facial contours. Expected lifetime of 12 to 18 months. For use by licensed healthcare professionals.
  • TEOSYAL RHA 1 Resilient hyaluronic acid filler for correction of fine lines including perioral rhytids, upper lip border, and philtrum. Expected lifetime of at least 12 months. For use by licensed healthcare professionals.
  • TEOSYAL RHA 2 Resilient hyaluronic acid filler (23 mg/mL HA) with 0.3% lidocaine for filling linear facial wrinkles and skin creases such as mild to moderate nasolabial folds. Designed to adapt to facial dynamics. Expected lifetime of 12 to 18 months. For use by licensed healthcare professionals.
  • TEOSYAL RHA 3 Resilient hyaluronic acid filler for filling deep facial wrinkles such as moderate to severe nasolabial folds, and FDA-authorized for lip augmentation. Designed to adapt to facial movements. Expected lifetime of 12 to 18 months. For use by licensed healthcare professionals.
  • TEOSYAL RHA 4 Resilient hyaluronic acid filler for filling deep wrinkles and folds in thick skin areas such as moderate to severe nasolabial folds and cheek augmentation. FDA-approved with Mepivacaine for midface augmentation. Expected lifetime of 15 to 18 months. For use by licensed healthcare professionals.
  • TEOSYAL RHA Kiss VolumeLIDO Lip filler with lidocaine in the RHA collection for correction of moderate to severe dynamic facial wrinkles and folds, lip augmentation, and lip fullness. Expected lifetime of 12 months. For use by licensed healthcare professionals.
  • TEOSYAL RHA Dynamic Volume New generation resilient hyaluronic acid filler for cheek augmentation and correction of age-related midface contour deficiencies in adults aged 22 years or older. Uses unique rheology to adapt to facial movements, providing natural-looking results lasting up to one year. For use by licensed healthcare professionals.
  • R-Energy Skin Quality System Comprehensive skin quality approach combining skin boosters (Redensity 1, RHA 1) with advanced dermocosmetics to restore hydration, luminosity, and long-term skin vitality. Works to hydrate, improve elasticity, refine texture, and strengthen skin resilience.
  • RHA Deep Repair Balm Post-procedure repair cream for skin recovery following aesthetic treatments. Part of the dermocosmetics product range, sold directly to consumers via the company e-commerce platform and through healthcare professionals for patient recommendations.

Quantifiable outcome

  • Products approved and commercialized in 90+ countries worldwide

Companies that use Teoxane Laboratories Geneva

Customer profile

Segments2 records

Ideal customer profiles2 records

Teoxane Laboratories Geneva technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Teoxane Laboratories Geneva partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Revance TherapeuticscoreChannel Partner/ Reseller/ Distributor

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Teoxane Laboratories Geneva competitors and assessment

Company assessment

Broad incumbents

  • Galderma: Galderma is the global leader in dermatology aesthetics and the maker of Restylane, the largest HA dermal filler franchise directly competing with Teoxane's TEOSYAL RHA line. Both companies target the same HCP channel (dermatologists, plastic surgeons, aesthetic physicians) with comparable injectable HA products.
  • AbbVie (Allergan Aesthetics): AbbVie's Allergan Aesthetics division markets the Juvéderm collection (including Voluma XC, Teoxane's direct benchmark in the RHA Dynamic Volume Phase III trial). Both compete in facial rejuvenation HA fillers sold through HCPs globally.

Direct peers

  • Prollenium Medical Technologies: Prollenium manufactures the Revanesse line of HA dermal fillers, directly competing with Teoxane's RHA products in the global aesthetics market with similar technology positioning and HCP go-to-market.
  • Merz Aesthetics: Merz Aesthetics markets Belotero Balance (HA filler) and Radiesse (calcium hydroxylapatite), competing directly with Teoxane's RHA and PureSense lines in the medical aesthetics channel. Both are privately-positioned mid-size aesthetics specialists with global distribution.
  • Sinclair Pharma: Sinclair Pharma (acquired by Huadong Medicine) markets HA dermal fillers (MaiLi) and complementary aesthetics products, making it a direct competitor to Teoxane in the premium HA filler category globally.
  • Revance Therapeutics: Revance is Teoxane's exclusive US distribution partner for the RHA collection and also markets its own DAXI neuromodulator, making it both a channel partner and a competitor in the US medical aesthetics market serving the same HCPs.
  • Croma-Pharma: Croma-Pharma is an Austrian family-owned manufacturer of HA-based dermal fillers and skincare, closely comparable to Teoxane as a European mid-size aesthetics specialist with similar product positioning and private ownership structure.

Regional players

  • Evolus: Evolus is a US-focused aesthetics company marketing Jeuveau (neuromodulator) and expanding into adjacent categories, competing with Teoxane indirectly for the same HCP aesthetic customer base in North America.

Emerging players

  • Hugel (Chaeum, Dermax): Hugel is a Korean aesthetics and botulinum toxin manufacturer that has expanded into HA dermal fillers, competing with Teoxane in the global market with cost-competitive offerings and growing regulatory approvals.
  • LG Chem (Yvoire): LG Chem's life sciences division markets Yvoire, a HA dermal filler line, competing with Teoxane in Asian and select global markets as part of a broader conglomerate-backed aesthetics push.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

Teoxane Laboratories Geneva social profiles

Digital presence

Teoxane Laboratories Geneva compliance and trust

Trust signal

Compliance3 records

Teoxane Laboratories Geneva financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Teoxane Laboratories Geneva leadership team

Management profile

Number of profiles

Profiles3 records

Teoxane Laboratories Geneva subsidiaries and ownership

Company hierarchy

Subsidiaries11 records

Teoxane Laboratories Geneva funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Teoxane Laboratories Geneva M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Teoxane Laboratories Geneva

What does Teoxane Laboratories Geneva do?

Teoxane designs, manufactures, and globally distributes a complete range of hyaluronic acid (HA) dermal fillers under the TEOSYAL PureSense and TEOSYAL RHA product lines, sold as Class III medical devices exclusively to licensed healthcare professionals for facial rejuvenation, wrinkle correction, and volume restoration. The portfolio is complemented by a dermocosmetics skincare range (including RHA Deep Repair Balm and the R-Energy skin quality system) sold both to professionals for patient recommendations and directly to end consumers via the company's e-commerce platform.

Is Teoxane Laboratories Geneva a public or private company?

Teoxane Laboratories Geneva is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Teoxane Laboratories Geneva founded?

Teoxane Laboratories Geneva was founded in 2003. It employs 501 to 1,000 people.

Where is Teoxane Laboratories Geneva based?

Teoxane Laboratories Geneva is headquartered in Geneva, Switzerland, in the Europe region.

How does Teoxane Laboratories Geneva make money?

Two revenue lines are on record. Dermal Filler Product Sales are the primary driver. The others are dermocosmetics Sales.

Who are Teoxane Laboratories Geneva's main competitors?

Broad incumbents on record are Galderma and AbbVie (Allergan Aesthetics). Direct peers are Prollenium Medical Technologies, Merz Aesthetics, Sinclair Pharma, Revance Therapeutics and Croma-Pharma. Evolus is listed as a regional player. Emerging players are Hugel (Chaeum, Dermax) and LG Chem (Yvoire).

Does Teoxane Laboratories Geneva have an API?

No public API is recorded for Teoxane Laboratories Geneva.

What industry is Teoxane Laboratories Geneva in?

Teoxane Laboratories Geneva's product category is Medical Aesthetics. Its primary akta.pro industry code is CRABAAAF, Dermocosmetics & Medical-Grade Skincare, with a secondary code of CRABAAAB, Treatment Skincare (Serums, Actives, Acne & Anti-aging). Its NAICS code is 339113 and its SIC code is 2844.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRevance and Teoxane Announce the FDA Approval of RHA Redensity® Eye for Undereye HollowingRevance and Teoxane announced FDA approval of RHA Redensity Eye for correcting moderate to severe undereye volume deficiencies in adults 22 and older. The 52-week U.S. pivotal study showed 93% of patients improved at 3 months, with results lasting up to 12 months without touch-ups.BioSpaceRevance and Teoxane Announce the FDA Approval of RHA Redensity® Eye for Undereye HollowingRevance and Teoxane announced FDA approval of RHA Redensity Eye for correcting moderate to severe undereye volume deficiencies in adults 22 and older. The 52-week U.S. pivotal study showed 93% of patients improved at 3 months, with results lasting up to 12 months without touch-ups.EIN PresswireDermal Fillers and Botulinum Toxin Market Growth Outlook Across APAC, Europe, USA & Saudi Arabia Through 2035The global dermal fillers and botulinum toxin market is projected to grow from USD 6.8 billion in 2025 to USD 9.3 billion by 2035, registering a steady CAGR of 3.2%, driven by rising consumer preference for non-invasive aesthetic treatments with natural-looking results and minimal recovery time. The growth is attributed to social media influence, advancements in treatment precision, and expanding adoption across diverse age groups in regions including North America, APAC, Europe, and the Middle East. Key market players including Allergan, Galderma, Merz Pharma, and TEOXANE Laboratories are integrating AI-powered facial mapping, clinical robotics, and dynamic dosing algorithms to refine patient outcomes and reduce procedural variability.PR NewswireRevance Launches the Teoxane RHA® Collection with MepivacaineRevance has launched the Teoxane RHA Collection with Mepivacaine in the U.S. market, replacing lidocaine with mepivacaine as the anesthetic in hyaluronic acid dermal fillers. The product, which received FDA approval in 2023 and is manufactured by Teoxane SA in Switzerland, represents the first major anesthetic innovation in the filler category in nearly two decades. Clinical studies found the mepivacaine formulation provides comparable pain control and safety to lidocaine while potentially reducing injection site bruising due to less local vasodilation.PR NewswireThe Brand Behind Disruptive Dermal Fillers Enters U.S. Skincare Market: Teoxane's Swiss-Made Dermocosmetics Now Just a Click AwayTeoxane, a Swiss aesthetic medicine company specializing in hyaluronic acid fillers, has launched its dermocosmetics line directly to U.S. consumers through its website teoxane.us, marking the first time these products are available to the general public rather than only through aesthetic professionals. The product line features the company's patented RHA® (Resilient Hyaluronic Acid) technology and includes serums, eye treatments, and advanced skincare priced between $44 and $168. Founded in Geneva in 2003, Teoxane has a presence in 94 markets with over 600 employees and now brings its professional-grade skincare formulations to the growing U.S. dermocosmetics market.PR NewswireRevance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th DeadlineCrown Laboratories has urged Revance Therapeutics stockholders to tender their shares by February 4, 2025, at $3.65 per share following the withdrawal of a competing proposal by Teoxane SA and unanimous approval from Revance's Board of Directors. The transaction is expected to close by February 6, 2025, contingent upon receiving tenders for more than 50% of Revance's outstanding shares. As of late January, approximately 10.4% of shares had already been validly tendered.YahooTeoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in CashTeoxane SA proposed to acquire Revance Therapeutics for $3.60 per share in cash, a 16% premium over Revance's amended agreement with Crown Laboratories. Teoxane, which owns 6.2% of Revance, expects limited regulatory risks and has secured financing discussions. The deal would close subject to regulatory approvals.RevanceScience-Powered InnovationThe article presents the prescribing information and safety warnings for DAXXIFY, a neuromuscular blocking agent indicated for glabellar lines and cervical dystonia, distributed by Revance. It also details the indications and safety profiles for the Teoxane RHA Collection of hyaluronic acid fillers, which are exclusively distributed by Revance in the United States.GlobeNewswireIndia Skin Boosters Market Size, Share & Trends Analysis Report 2024-2030 Featuring Sinclair Pharma, Medytox, AbbVie, Merz Pharma, Galderma, Teoxane, IBSA farmaceutici, Allergan, PharmaResearchThe India skin boosters market is projected to grow from $21.66 million in 2023 to $43.02 million by 2030, a CAGR of 10.5%. The mesotherapy segment led with 54.4% revenue share in 2023, and female consumers held 85.4% of the market. Major players are expanding production facilities and investing in R&D to meet rising demand.GlobeNewswireGlobal Dermal Fillers Market Insights, 2024-2029 - AbbVie, Galderma, Merz Pharma, Sinclair, and Teoxane Dominate the $9.98 Billion Projected MarketThe global dermal fillers market is projected to grow from $6.18 billion in 2023 to $9.98 billion by 2029, a CAGR of 8.3%. Hyaluronic acid fillers held the largest material share, and the U.S. led North America, while APAC showed the highest growth.